NCT07109999Recruiting
Biomarker-based Alzheimer's Disease Cohort Study (BASIC)
Source: ClinicalTrials.gov · Last updated 7 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2835 (estimated)
- First submitted
- 25 May 2025
- Start date
- 1 Jan 2019
- Primary completion date
- 31 Dec 2050
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Alzheimer disease
- NCT number
- NCT07109999
What you commit to
- Study type: Observational
- Planned participants: 2835
- From 1 Jan 2019 to the primary completion date, 31 Dec 2050
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- (1) Individuals who are unable to complete the assessment due to severe psychological or physiological disorders.
Who the study is looking for
- (1) Patients aged 40 years or older;
- (2) Visiting Xuanwu Hospital, Capital Medical University;
- (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011);
- (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests;
- (5) Providing informed consent.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital of Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.